U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07117487) titled 'A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants >=60 Years of Age' on Aug. 05.
Brief Summary: The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged >=60 years.
Study Start Date: Aug. 05
Study Type: INTERVENTIONAL
Condition:
Respiratory Syncytial Virus
Intervention:
BIOLOGICAL: mRNA-1345
Suspension for injection
Recruitment Status: RECRUITING
Spo...